Renal Cell Carcinoma of Variant Histology: New Biologic Understanding Leads to Therapeutic Advances

Abstract

Renal cell carcinoma (RCC) is one of the 10 most commonly diagnosed solid tumors. Most RCCs are histologically defined as clear cell, comprising approximately 75% of diagnoses. However, the remaining RCC cases are composed of a heterogeneous combination of diverse histopathologic subtypes, each with unique pathogeneses and clinical features. Although the therapeutic approach to both localized and metastatic RCCs has dramatically changed, first with the advent of antiangiogenic targeted therapies and more recently with the approval of immune checkpoint inhibitor (ICI)-based combinations, these advances have primarily benefited the clear cell RCC patient population. As such, there remains critical gaps in the optimization of treatment regimens for patients with non-clear cell, or variant, RCC histologies. Herein, we detail recent advances in understanding the biology of RCC with variant histology and how such findings have guided novel clinical studies investigating precision oncology approaches for these rare subtypes. Among the most common variant histology RCCs are papillary RCC, comprising approximately 15%-20% of all diagnoses. Although a histopathologically diverse subset of tumors, papillary RCC is canonically associated with amplification of the MET protooncogene; recently completed and ongoing trials have investigated MET-directed therapies for this patient population. Finally, we discuss the unique biology of RCC with sarcomatoid dedifferentiation and the recent clinical findings detailing its paradoxical sensitivity to ICIs.

FIG 1.

Overview and relative proportion of histologic subtypes comprising RCC diagnoses. Pathology images retrieved from pathologyoutlines.com. RCC, renal cell carcinoma.

FIG 2.

Schematics of ongoing randomized trials for patients with pRCC: (A) PAPMET2 (ClinicalTrials.gov identifier: NCT05411081), (B) SAMETA (ClinicalTrials.gov identifier: NCT05043090), (C) STELLAR-304 (ClinicalTrials.gov identifier: NCT05678673), and (D) SUNIFORECAST (ClinicalTrials.gov identifier: NCT03075423). DCR, disease control rate; DoR, duration of response; HRQoL, health-related quality of life; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; pRCC, papillary renal cell carcinoma; R, randomize; RCC, renal cell carcinoma; SoC, standard of care.